Consumer medicine information

Dexdor

Dexmedetomidine

BRAND INFORMATION

Brand name

Dexdor

Active ingredient

Dexmedetomidine

Schedule

SUMMARY CMI

DEXDOR^®

Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.

1. Why am I being given DEXDOR?

DEXDOR contains the active ingredient dexmedetomidine hydrochloride. DEXDOR is used in adult patients who need to be kept calm or sleepy when either:

on a breathing machine (ventilator) in the Intensive Care Unit (ICU), or
unaided by a breathing machine before a surgical or other procedure.

For more information, see Section 1. Why am I being given DEXDOR? in the full CMI.

2. What should I know before I am given DEXDOR?

Do not use if you have ever had an allergic reaction to DEXDOR or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I am given DEXDOR? in the full CMI.

3. What if I am taking other medicines?

Some medicines may interfere with DEXDOR and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

4. How is DEXDOR given?

DEXDOR is diluted with another liquid in an IV bag and given as a ‘drip’ through a vein (intravenous infusion) by a doctor or nurse. Your doctor or anaesthetist will decide how fast the infusion will be given to keep you at the right depth of sleep or calmness, and how long you need it.

More information can be found in Section 4. How is DEXDOR given? in the full CMI.

5. What should I know while being given DEXDOR?

Things you should do	While DEXDOR is only given when you are in the ICU or surgery, some of it may remain in the body for a short time afterwards. Tell your doctor straight away that you have been given DEXDOR before you start a new medicine, undergo further surgery or blood tests since these may be affected by DEXDOR. Tell your doctor if you find out that you are pregnant. If you feel dizzy, light-headed or faint when getting out of bed or standing up, do so slowly.
Driving or using machines	DEXDOR may cause dizziness, light-headedness, tiredness or drowsiness and may therefore affect alertness in some people. Avoid driving or operating machinery if you experience these symptoms and ask your doctor for advice.
Looking after your medicine	Your doctor, anaesthetist and nurse are responsible for storing, preparing, giving and discarding DEXDOR.

For more information, see Section 5. What should I know while being given DEXDOR? in the full CMI.

6. Are there any side effects?

Common side effects such as dizziness, light-headedness, nausea, vomiting, fever, dry mouth, feeling thirsty, constipation, diarrhoea, agitation, confusion, tiredness, swelling, sweating more, blood sugar changes, vision changes and passing less or more urine are usually mild and short-lived. More serious side effects such as heart rate changes, breathing problems, chest pain or tightness, bruising, overheating, excessive thirst, extreme fatigue, lack of energy, restlessness, confusion, muscle twitches and seizures may require urgent medical attention.

For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.

FULL CMI

DEXDOR^®

Active ingredient: dexmedetomidine hydrochloride

Consumer Medicine Information (CMI)

This leaflet provides important information about DEXDOR. You should also speak to your doctor, anaesthetist or pharmacist if you would like further information or if you have any concerns or questions about being given DEXDOR.

Where to find information in this leaflet:

1. Why am I being given DEXDOR?
2. What should I know before I am given DEXDOR?
3. What if I am taking other medicines?
4. How is DEXDOR given?
5. What should I know while being given DEXDOR?
6. Are there any side effects?
7. Product details

1. Why am I being given DEXDOR?

DEXDOR contains the active ingredient dexmedetomidine hydrochloride. DEXDOR is a sedative (calming agent) for adults who need to be calmed or sleepy when on a breathing machine (ventilator) in the Intensive Care Unit (ICU). DEXDOR may also be given to adults who are not ventilated before a surgical or other procedure.

2. What should I know before I am given DEXDOR?

Warnings

DEXDOR should not be given to you if:

you are allergic to dexmedetomidine or sodium chloride.
Always check the ingredients at the end of this leaflet to make sure you can be given this medicine.

Symptoms of an allergic reaction include shortness of breath; wheezing or difficulty breathing; swelling of the face, lips, tongue or other parts of the body; rash, itching or hives on the skin.

Check with your doctor if you:

have any other medical conditions such as heart problems, high or low blood pressure, diabetes, kidney or liver problems.
take any medicines for any other condition
elderly patients 65 years or older may be more prone to the blood pressure lowering effects of DEXDOR.

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Check with your doctor if you are pregnant or intend to become pregnant. Dexmedetomidine may affect your developing baby if given during pregnancy.

Talk to your doctor if you are breastfeeding or intend to breastfeed. Since it also passes into breast milk, it is possible that your baby may be affected.

Your doctor can discuss with you the risks and benefits of being given DEXDOR.

Children and adolescents

Information on the safety of dexmedetomidine in children and adolescents is limited, therefore it is not recommended for use in patients below 18 years of age.

3. What if I am taking other medicines?

Tell your doctor, anaesthetist or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines that help you sleep, calm down or relieve pain such as sevoflurane, isoflurane, propofol, midazolam, alfentanil and opioids may enhance the effects of dexmedetomidine. Your doctor may adjust your dose to achieve the desired level of sleepiness or calmness.

If you are using medicines which lower your blood pressure and heart rate, co-administration with Dexdor may enhance this effect.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect DEXDOR.

4. How is DEXDOR given?

How much is given

DEXDOR is diluted with another liquid, usually sodium chloride solution (saline), in an IV bag and given as a controlled ‘drip’ through a vein (intravenous infusion) by a doctor or nurse.
Your doctor or anaesthetist will decide how fast you receive the diluted solution to keep you at the right depth of sleep or calmness while on the breathing machine or during a surgical procedure. This may depend on factors such as your weight, condition and reaction.
DEXDOR infusion may be given continuously for up to 24 hours, but your doctor or anaesthetist will decide how long you need it.
Your doctor, anaesthetist and nurses will monitor your condition while you are being given DEXDOR.

If you are given too much DEXDOR

As DEXDOR is given to you under the supervision of a doctor or anaesthetist, it is very unlikely that you will receive too much. However, if DEXDOR is no longer being given but you experience side effects (see Section 6. Are there any side effects?), tell your doctor. You may need urgent medical attention.

If you have serious side effects after already leaving the ICU or surgery, you should immediately:

phone the Poisons Information Centre
(by calling 13 11 26), or
contact your doctor, or
go to the Emergency Department at your nearest hospital.

5. What should I know while being given DEXDOR?

Things you should do

While DEXDOR is only given when you are in the ICU or are undergoing a surgical or other procedure, some of the drug may remain in your body for a short time afterwards.

Tell your doctor straight away that you have been or are being given DEXDOR if you:

Are about to be started on any new medicine
Are going into surgery for another procedure, as it may affect other medicines used during surgery
Are about to have any blood tests, as it may interfere with the results
Find out that you are pregnant.

Getting out of bed or standing up

If you feel light-headed, dizzy or faint when getting out of bed or standing up, do so slowly so that your body can get used to the changes in position and blood pressure. If this problem continues or gets worse, talk to your doctor.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how DEXDOR has affected you.

DEXDOR may cause dizziness, light-headedness, tiredness or drowsiness and may therefore affect alertness in some people. If you experience any of these conditions, do not drive, operate machinery or do anything else that could be dangerous.

Ask your doctor for advice on when you can resume these activities.

Looking after your medicine

DEXDOR is stored in the hospital pharmacy or kept on the ICU ward where the temperature stays below 25°C. Your doctor, anaesthetist or nurse is responsible for storing, preparing and giving the infusion solution, and discarding any unused solution.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

See the information below and, if you need to, ask your doctor, anaesthetist or nurse if you have any further questions about side effects.

Less serious side effects

Less serious side effects	What to do
dizziness, light-headedness nausea and/or vomiting high temperature dry mouth constipation or diarrhoea agitation, confusion or tiredness swelling in the arms or legs (fluid retention) changes in blood sugar levels increased sweating changes to vision changes to passing urine feeling thirsty	Speak to your doctor if you have any of these less serious side effects and they worry you. These are usually mild and short-lived.

Serious side effects

Serious side effects

What to do

changes in heart rate including slowing or quickening of heartbeat
wheezing, shortness of breath, rapid breathing or breathing difficulties
pressure, tightness or pain in the chest or arms that may spread to the neck, jaw or back
unusual bruising
overheating of your body that you can't cool by usual methods
excessive thirst, extreme fatigue, lack of energy, confusion, muscle twitching or spasms, restlessness, seizures

Tell your doctor or nurse straight away, or if you have already left the ICU or surgery, go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor if you notice anything else that may be making you feel unwell.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

7. Product details

This medicine is only given under a doctor's supervision in a hospital or surgery.

What DEXDOR contains

Active ingredient (main ingredient)	dexmedetomidine (as hydrochloride)
Other ingredients (inactive ingredients)	sodium chloride, water for injections

DEXDOR must not be given to you if you are allergic to any of these ingredients.

What DEXDOR looks like

DEXDOR is a clear, colourless concentrated solution. It is available in:

2 mL clear glass ampoules containing 200 micrograms dexmedetomidine each in packs of 5 or 25 ampoules per carton (AUST R 379412),
4 mL clear glass vials containing 400 micrograms dexmedetomidine each in packs of 4 vials per carton (AUST R 379411), and
10 mL clear glass vials containing 1000 micrograms dexmedetomidine each in packs of 4 vials per carton (AUST R 379410).

Who distributes DEXDOR

Orion Pharma (Aus) Pty Limited
Level 24, Tower 3, 300 Barangaroo Avenue
Sydney NSW 2000, Australia
Telephone: 1800 861 913

This leaflet was prepared in December 2023.

Published by MIMS March 2024

BRAND INFORMATION

Brand name

Dexdor

Active ingredient

Dexmedetomidine

Schedule

1 Name of Medicine

Dexmedetomidine (as hydrochloride).

2 Qualitative and Quantitative Composition

200 microgram/2 mL.

Each 2 mL ampoule of Dexdor contains 236 micrograms of dexmedetomidine hydrochloride (equivalent to 200 micrograms dexmedetomidine base).

400 microgram/4 mL.

Each 4 mL vial of Dexdor contains 472 micrograms of dexmedetomidine hydrochloride (equivalent to 400 micrograms dexmedetomidine base).

1000 microgram/10 mL.

Each 10 mL vial of Dexdor contains 1180 micrograms of dexmedetomidine hydrochloride (equivalent to 1000 micrograms dexmedetomidine base).
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Dexdor dexmedetomidine (as hydrochloride) concentrated injection is a sterile, non-pyrogenic solution suitable for intravenous (IV) infusion.
Dexdor concentrated injection is supplied as a clear, colourless, isotonic solution with a pH of 4.5-7.0. It is presented in 2 mL ampoule, 4 mL vial or 10 mL vial, and must be diluted prior to use.

4 Clinical Particulars

4.1 Therapeutic Indications

Intensive care unit (ICU) sedation.

For sedation of initially intubated adult patients during treatment in an intensive care setting. The use of Dexdor by continuous infusion in these patients should not exceed 24 hours.

Procedural sedation.

For sedation of non-intubated adult patients prior to and/or during surgical and other procedures.

4.2 Dose and Method of Administration

Note.

Dexmedetomidine should be administered only by persons skilled in anaesthetics or in the management of patients in the intensive care setting. Due to the known pharmacological effects, patients should be continuously monitored.
Clinically significant events of bradycardia and sinus arrest have been associated with dexmedetomidine hydrochloride administration in young, healthy volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration of dexmedetomidine hydrochloride.

Adults.

Dexmedetomidine should be individualised and titrated to the desired clinical effect.
ICU sedation.

Initiation.

For adult patients, Dexdor may be initiated with a loading infusion of 1 (one) microgram/kg over 10 to 20 minutes, if needed. The use of Dexdor by continuous infusion in these patients should not exceed 24 hours.
The use of loading dose of dexmedetomidine was associated with an increased rate of adverse event, including hypotension, hypertension and bradycardia, in clinical trials involving adult ICU patients.
For patients being converted from alternate sedative therapy a loading dose may not be required.

Maintenance of ICU sedation.

Adult patients will generally require a maintenance infusion of 0.2 to 1 microgram/kg/hr. The rate of the maintenance infusion should be adjusted to achieve the desired level of sedation. As a guide, it is recommended that 0.4 microgram/kg/hr should be the initial maintenance infusion. If after approximately 5 minutes sedation is not adequate, the rate of infusion can be increased in increments of 0.1 microgram/kg/hr or higher. Dosages as low as 0.05 microgram/kg/hr have been used in clinical studies.
A dose reduction for both the loading and maintenance infusions should be considered in patients with impaired hepatic function and in patients over 65 years of age (see Section 4.4 Special Warnings and Precautions for Use; Section 5.2 Pharmacokinetic Properties).
Dexmedetomidine has been continuously infused in mechanically ventilated patients prior to extubation, during extubation, and post-extubation. It is not necessary to discontinue Dexdor prior to extubation.
Procedural sedation. Based on sedation scores, the loading infusion provides clinically effective onset of sedation 10 to 15 minutes after start of infusion.

Initiation.

For adult patients, Dexdor is generally initiated with a loading infusion of 1 (one) microgram/kg over 10 to 20 minutes for sedation of non-intubated patients undergoing surgical and other procedures, as well as, for initiation of awake fibreoptic intubation.
For patients with impaired hepatic function and in patients over 65 years of age, the loading dose may be omitted or reduced, e.g. 0.5 microgram/kg over 10 minutes may be suitable.
For patients undergoing less invasive procedures, such as ophthalmic surgery, the loading dose may be reduced, e.g. 0.5 micrograms/kg over 10 minutes may be suitable.

Maintenance of procedural sedation.

Following the loading dose, maintenance dosing of Dexdor should generally be initiated at 0.6 microgram/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 microgram/kg/hr for all procedures. The rate of the maintenance infusion should be adjusted to achieve the targeted level of sedation.
Following the loading dose in awake fibreoptic intubation, a fixed maintenance dose of 0.7 microgram/kg/hr should be used until the endotracheal tube is secured.
A dose reduction should be considered in patients with impaired hepatic function and in patients over 65 years of age (see Section 4.4 Special Warnings and Precautions for Use; Section 5.2 Pharmacokinetic Properties).

Paediatric use.

Safety of dexmedetomidine has not been sufficiently established in paediatric patients (see Section 4.4 Special Warnings and Precautions for Use).

Administration.

A controlled infusion device should be used to administer dexmedetomidine.
Strict aseptic technique must always be maintained during handling of dexmedetomidine infusion.

Preparation.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Dexdor must be diluted with 0.9% sodium chloride injection to achieve required concentration (4 micrograms/mL) prior to administration. Preparation of infusion solutions is the same, whether for the loading dose or maintenance.
To prepare the required volume of infusion solution at a concentration of 4 micrograms/mL, withdraw the volume of Dexdor concentrated injection specified in the second column of Table 1 and add to the corresponding volume of diluent, e.g. 0.9% sodium chloride (column 3), to yield the total volume in column 4.

Shake gently to mix well. Use as soon as practicable after dilution to reduce microbiological hazard. If storage is necessary, hold at 2-8°C for not more than 24 hours. Parenteral products should be inspected visually for particulate matter and discolouration prior to administration.
The content of each ampoule or vial is for single use in one patient only. Discard any residue.

Compatibility.

Dexmedetomidine has been shown to be compatible when administered with the following intravenous fluids: Lactated ringers, 5% glucose in water, 0.9% sodium chloride in water, 20% mannitol in water.
Dexmedetomidine has been found to be compatible with water solutions of the following drugs when administered via Y-site injection: thiopental sodium, vecuronium bromide, pancuronium bromide, glycopyrronium bromide (glycopyrrolate), phenylephrine hydrochloride.
Dexmedetomidine hydrochloride is known to be absorbed by some types of natural rubber. Although Dexdor is dosed to effect, use of infusion equipment and components with synthetic or coated rubber gaskets is recommended.

4.3 Contraindications

Dexmedetomidine hydrochloride is contraindicated in patients with a known hypersensitivity to dexmedetomidine, or any of the excipients contained in Dexdor (see Section 6.1 List of Excipients).

4.4 Special Warnings and Precautions for Use

Drug administration.

Dexmedetomidine hydrochloride is for hospital use only. Dexdor should be administered only by persons skilled in the management of patients in the intensive care or operating room setting. Due to the known pharmacological effects of dexmedetomidine hydrochloride, patients should be continuously monitored (MAC: Monitored Anaesthesia Care) for early signs of hypotension, hypertension, bradycardia, respiratory depression, airway obstruction, apnoea, dyspnoea and/or oxygen desaturation while receiving dexmedetomidine hydrochloride. Supplemental oxygen should be immediately available and provided when indicated.
Continuous electrocardiogram (ECG), blood pressure, and oxygen saturation monitoring are recommended during infusion of Dexdor. Dexmedetomidine may cause reduced lacrimation. Lubrication of the patient's eyes should be considered when administering dexmedetomidine to avoid corneal dryness.
Dexdor is only to be used for procedural sedation with the provision of appropriate monitoring and under the constant supervision of an appropriately trained medical practitioner. Although dexmedetomidine has sedative effects it has not been shown to be amnestic. Should amnesia be desired during procedural sedation then a drug with amnestic properties (such as a benzodiazepine) should be co-administered.

Hypotension, bradycardia and sinus arrest.

Clinical events of bradycardia and sinus arrest have been associated with dexmedetomidine administration in young, healthy adult volunteers with high vagal tone or with different routes of administration including rapid intravenous or bolus administration of dexmedetomidine.
Decreased blood pressure and/or heart rate may occur with the administration of dexmedetomidine. Dexmedetomidine decreases sympathetic nervous activity and therefore, these effects may be expected to be most pronounced in patients with desensitised autonomic nervous system control (i.e. ageing, diabetes, chronic hypertension, severe cardiac disease).
Reports of hypotension and bradycardia have been associated with dexmedetomidine infusion. Some of these cases have resulted in fatalities. If medical intervention is required, treatment may include decreasing or stopping the infusion of Dexdor increasing the rate of IV fluid administration, elevation of the lower extremities, and use of pressor agents. Because dexmedetomidine has the potential to augment bradycardia induced by vagal stimuli, clinicians should be prepared to intervene. The intravenous administration of anticholinergic agents (e.g. glycopyrrolate, atropine) should be considered to modify vagal tone. In clinical trials, glycopyrrolate or atropine were effective in the treatment of most episodes of dexmedetomidine induced bradycardia. However, in some patients with significant cardiovascular dysfunction, more advanced resuscitative measures were required.
Caution should be exercised when administering Dexdor to patients with advanced heart block and/or severe ventricular dysfunction. Because dexmedetomidine decreases sympathetic nervous system activity, hypotension and/or bradycardia may be expected to be more pronounced in hypovolaemic patients and in those with diabetes mellitus or chronic hypertension and in elderly patients.
In situations where other vasodilators or negative chronotropic agents are administered, co-administration of dexmedetomidine could have an additive pharmacodynamic effect and should be administered with caution.
Clinical events of bradycardia or hypotension may be potentiated when dexmedetomidine is used concurrently with propofol or midazolam. Therefore, consider a reduction in the dose of midazolam or propofol.
Elderly patients over 65 years of age, or diabetic patients, are more prone to hypotension with the administration of dexmedetomidine. All episodes either spontaneously reversed or were treated with standard therapy.

Transient hypertension.

Transient hypertension has been observed primarily during the loading infusion, associated with initial peripheral vasoconstrictive effects of dexmedetomidine and relatively higher plasma concentrations achieved during the loading infusion. If intervention is necessary, reduction of the loading infusion rate may be considered. Following the loading infusion, the central effects of dexmedetomidine dominate and the blood pressure usually decreases.

Arousability.

Patients receiving dexmedetomidine have been observed to be rousable and alert when stimulated. This is an expected component of dexmedetomidine sedation and should not be considered a lack of efficacy in the absence of other clinical signs and symptoms.

Withdrawal.

Although not specifically studied, if dexmedetomidine is administered chronically and stopped abruptly, withdrawal symptoms similar to those reported for another alpha₂-adrenergic agent, clonidine, may result. These symptoms include nervousness, agitation, and headaches, accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma. Dexmedetomidine should not be administered for greater than 24 hours.

Procedural sedation.

In adult subjects, withdrawal symptoms were not seen after discontinuation of short-term infusions of dexmedetomidine (< 6 hrs).

Adrenal insufficiency.

Dexmedetomidine had no effect on ACTH-stimulated cortisol release in dogs after a single dose; however, after the subcutaneous (SC) infusion of dexmedetomidine for one week, the cortisol response to ACTH was diminished by approximately 40%.
In a clinical study, prolonged infusions of dexmedetomidine at doses up to 1.4 microgram/kg/hr were not associated with significant adrenocortical suppression.

Hyperthermia.

Dexmedetomidine may induce hyperthermia that may be resistant to traditional cooling methods. Dexdor should be discontinued and hyperthermia should be managed with conventional medical measures.

Use in hepatic impairment.

Since dexmedetomidine clearance decreases with increasing severity of hepatic impairment, dose reductions should be considered in patients with impaired hepatic function (see Section 4.2 Dose and Method of Administration).

Risk of mortality in ICU patients ≤ 65 years old.

Use of dexmedetomidine greater than 24 hours has been associated with an increased mortality in critically ill adult ICU patients 65 years of age and younger compared to usual care (see Section 5.1 Pharmacodynamic Properties, Clinical trials).

Seizures.

Dexmedetomidine lacks the anticonvulsant action of some other sedatives and so will not suppress underlying seizure activity.

Incompatibility.

Dexmedetomidine has been shown to be incompatible when administered with the following drugs: amphotericin B, diazepam (see Section 6.2 Incompatibilities).

Use in the elderly.

Dexmedetomidine is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in elderly patients, and it may be useful to monitor renal function (see Section 5.1 Pharmacodynamic Properties, Clinical trials).

Paediatric use.

The safety of dexmedetomidine in paediatric patients below 18 years of age has not been sufficiently established for procedural or ICU sedation. Therefore, Dexdor is not recommended in this population (see Section 4.2 Dose and Method of Administration; Section 5.1 Pharmacodynamic Properties, Clinical trials).

Effects on laboratory tests.

No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Anaesthetics/sedatives/hypnotics/opioids.

Co-administration of dexmedetomidine is likely to lead to an enhancement of effects with anaesthetics, sedatives, hypnotics, and opioids. Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, alfentanil, and midazolam. No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, alfentanil, and midazolam were demonstrated. However, due to pharmacodynamic effects, when co-administered with dexmedetomidine, a reduction in dosage with these agents may be required.

Neuromuscular blockers.

No clinically meaningful increases in the magnitude of neuromuscular blockade and no pharmacokinetic interactions were observed with dexmedetomidine and rocuronium administration.

Drugs with cardiovascular activities.

The possibility of enhanced hypotensive and bradycardic effects should be considered in patients receiving other medicinal products causing these effects, for example beta blockers, although additional effects in an interaction study with esmolol were modest.

Cytochrome P450.

In vitro studies indicate that clinically relevant cytochrome P450 mediated drug interactions are unlikely. Dexmedetomidine has shown strongest properties for inhibition of CYP2D6, CYP3A4 and CYP2B6. Use caution during concomitant administration of Dexdor with other medicines metabolized by CYP2D6, CYP3A4 and CYP2B6 enzymes.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

Dexmedetomidine did not affect reproductive capacity or fertility in male or female rats after daily subcutaneous injections at doses up to 54 microgram/kg/day for 10 weeks prior to mating in males and 3 weeks prior to mating and during mating in females. Systemic exposure (AUC_0-24h) at this dose level was less than anticipated at the maximum recommended human dose of 17.8 microgram/kg.
(Category B1¹)
Radiolabelled dexmedetomidine administered subcutaneously to female rats on gestation day 18 crossed the placental barrier to foetal tissue. Teratogenic effects were not observed following administration of dexmedetomidine at subcutaneous doses up to 200 microgram/kg/day in rats or IV doses up to 96 microgram/kg/day in rabbits. Systemic exposure (AUC_1-24h) at these dose levels was 3 to 5 times greater than those in humans at the maximum recommended dose of 17.8 microgram/kg. In rats, foetal and pup body weights were reduced at SC doses ≥ 6 microgram/kg/day, post-implantation loss was increased at 200 microgram/kg/day, and perinatal mortality was increased at SC doses ≥ 18 microgram/kg/day. These findings are consistent with those of clonidine, another alpha₂-adrenoreceptor agonist.
Dexmedetomidine has no effect on foetal body weight or embryo foetal viability at IV doses as high as 96 microgram/kg/day in rabbits. Dexmedetomidine also produced delayed motor development in rat pups at a dose of 32 microgram/kg (less than the maximum recommended human intravenous dose). No such effects were observed at a dose of 2 microgram/kg.
There are no adequate and well-controlled studies in pregnant women. Dexmedetomidine has been shown to cross the placental barrier in human published studies. It has been reported that prenatal exposure to dexmedetomidine may be associated with some degree of functional impairment at birth in some neonates. Dexmedetomidine should be used during pregnancy only if the potential benefits justify the potential risk to the foetus.

Labour and delivery.

The safety of dexmedetomidine in labour and delivery has not been studied and is, therefore, not recommended for obstetrics, including caesarean section deliveries. Perioperative administration of dexmedetomidine in pregnant women receiving general anaesthesia for elective caesarean section was associated with a longer time to clinical recovery and extubation compared with remifentanil.
¹ Category B1: Drugs which have been taken only by a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects in the human foetus having been observed. Studies in animals have not shown evidence of an increased occurrence of foetal damage.
Dexmedetomidine is excreted in human milk, but no studies assessing the effects of dexmedetomidine in breastfed children and on milk production have been performed. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for dexmedetomidine and any potential adverse effects on the breastfed child from dexmedetomidine.
A lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk for 24 hours after receiving dexmedetomidine in order to minimise potential drug exposure to a breastfed neonate.
Radiolabelled dexmedetomidine administered subcutaneously to lactating female rats was distributed to, but did not accumulate in, milk.

4.7 Effects on Ability to Drive and Use Machines

Patients should be advised that performance of activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery or signing legal documents, may be impaired for some time after sedation.

4.8 Adverse Effects (Undesirable Effects)

ICU sedation.

Adverse event information derived from the placebo-controlled, continuous infusion trials of dexmedetomidine for sedation in the surgical ICU setting in which 387 patients received dexmedetomidine. In these studies, the mean total dose was 7.06 microgram/kg (SD = 2.86), mean dose per hour was 0.51 microgram/kg/hr (SD = 0.39) and the mean duration of infusion of 15.6 hours (range: 0.17 to 29.08). The population was between 19 to 83 years of age, 43% over 65 years of age, 73% male and 97% Caucasian. Overall, the most frequently observed treatment-emergent adverse events included hypotension, hypertension, nausea, bradycardia, fever, vomiting, hypoxia, tachycardia and anaemia (see Table 2).

Adverse event information derived from the midazolam-controlled, continuous infusion trial of dexmedetomidine for sedation in a predominantly medical ICU setting in which 244 patients received dexmedetomidine for long-term sedation. Treatment-emergent adverse events occurring at an incidence of > 5% are provided in Table 3. The mean total dose was 72.5 microgram/kg (range: 0.1 to 489.9), mean dose per hour was 0.83 microgram/kg/hr (range: 0.18 to 1.54) and the mean duration of infusion of 3.4 days (range: 0.02 to 15.6). The population was between 18 to 89 years of age, 46% over 65 years of age, 51% male and 79% Caucasian. The most frequent adverse events for this population were hypotension, tachycardia, bradycardia and systolic hypertension (see Section 4.4 Special Warnings and Precautions for Use).

The following adverse events occurred between 2 and 5% for dexmedetomidine and midazolam, respectively (see Table 4):

Procedural sedation.

Adverse event information is derived from the two primary phase 3 trials for procedural sedation in which 318 patients received dexmedetomidine. The mean total dose was 1.6 microgram/kg (range: 0.5 to 6.7), mean dose per hour was 1.3 microgram/kg/hr (range: 0.3 to 6.1) and the mean duration of infusion of 1.5 hours (range: 0.1 to 6.2). The population was between 18 to 93 years of age, 30% > 65 years of age, 52% male and 61% Caucasian.
Treatment-emergent adverse events occurring at an incidence of > 2% are provided in Table 5. The majority of the adverse events were assessed as mild in severity. The most frequent adverse events were hypotension, bradycardia, and dry mouth. Pre-specified criteria for the vital signs to be reported as Adverse Events are footnoted below the table. Respiratory depression and hypoxia was similar in the dexmedetomidine and placebo groups when evaluated against the pre-specified criteria. The incidence of absolute respiratory depression and hypoxia was less in the dexmedetomidine-treated patients than the placebo patients (3.04% vs 12.7%) in the MAC (Study 1) trial.

Post-marketing experience.

The adverse reactions that have been identified during post approval use of dexmedetomidine are provided in Table 6.
Hypotension and bradycardia were the most common adverse reactions associated with the use of dexmedetomidine during post approval use of the drug. Table 6 lists adverse drug reactions (ADRs) within each standard system organ class (SOC).

Dependence.

The dependence potential of dexmedetomidine has not been studied in humans.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

The tolerability of dexmedetomidine was noted in one study in which healthy adult subjects achieved plasma concentrations from 1.8 up to 13 times the upper boundary of the therapeutic range. The most notable effects observed in two subjects who achieved the highest plasma concentrations were 1st degree AV block and 2nd degree heart block. No haemodynamic compromise was noted with the AV block and the heart block resolved spontaneously within one minute.
Of five adult patients reported with overdose of dexmedetomidine in the Phase II/III ICU sedation studies, two had no symptoms reported; one patient received a 2 microgram/kg loading dose over 10 minutes (twice the recommended loading dose) and one patient received a maintenance infusion of 0.8 microgram/kg/hr. Two other patients who received a 2 microgram/kg loading dose over 10 minutes experienced bradycardia with or without hypotension. One patient, who received a loading bolus dose of undiluted (100 microgram/mL) dexmedetomidine (19.4 microgram/kg), had cardiac arrest from which he was successfully resuscitated.
For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Pharmacotherapeutic group: Psycholeptics, other hypnotics and sedatives.

Mechanism of action.

Dexmedetomidine is a relatively selective alpha₂-adrenoreceptor agonist with sedative pharmacologic properties.
The sedative actions of dexmedetomidine are believed to be mediated primarily by post-synaptic alpha₂-adrenoreceptors, which in turn act on inhibitory pertussis-toxin-sensitive G protein, thereby increasing conductance through potassium channels. The site of the sedative effects of dexmedetomidine has been attributed to the locus coeruleus. The analgesic actions are believed to be mediated by a similar mechanism of action at the brain and spinal cord level.
Alpha₂-selectivity was observed in animals following slow intravenous (IV) infusion of low and medium doses (10 - 300 microgram/kg). Both alpha₁ and alpha₂ activity was observed following slow IV infusion of high doses (≥ 1000 microgram/kg) or with rapid IV administration. Dexmedetomidine has a low affinity for beta adrenergic, muscarinic, dopaminergic and serotonin receptors.

Clinical trials.

ICU sedation. Two randomised, double-blind, parallel-group, placebo-controlled multicentre clinical trials included 754 patients being treated in a surgical intensive care unit (ICU). All patients were initially intubated and received mechanical ventilation.
These trials evaluated the sedative properties of dexmedetomidine by comparing the amount of rescue medication (midazolam in one trial and propofol in the second) required to achieve a specified level of sedation (using the standardised Ramsay sedation scale) between dexmedetomidine and placebo from onset of treatment to extubation or to a total treatment duration of 24 hours. The Ramsay level of sedation scale is displayed in Table 7.

In the first study, 175 adult patients were randomised to receive placebo and 178 to receive dexmedetomidine by intravenous infusion at a dose of 0.4 microgram/kg/hr (with allowed adjustment between 0.2 and 0.7 microgram/kg/hr) following an initial loading infusion of 1 (one) microgram/kg IV over 10 minutes. The study drug infusion rate was adjusted to maintain a Ramsay sedation score of ≥ 3. Patients were allowed to receive "rescue" midazolam as needed to augment the study drug infusion. In addition, morphine sulfate was administered for pain as needed. The primary outcome measure for this study was the total amount of rescue medication (midazolam) needed to maintain sedation as specified while intubated. Patients randomised to placebo received significantly more midazolam than patients randomised to dexmedetomidine (see Table 8).
A second prospective primary analysis assessed the sedative effects of dexmedetomidine by comparing the percentage of patients who achieved a Ramsay sedation score of ≥ 3 during intubation without the use of additional rescue medication. A significantly greater percentage of patients in the dexmedetomidine group maintained a Ramsay sedation score of ≥ 3 without receiving any midazolam rescue compared to the placebo group (see Table 8).

A prospective secondary analysis assessed the dose of morphine sulfate administered to patients in the dexmedetomidine and placebo groups. On average, dexmedetomidine-treated patients received less morphine sulfate for pain than placebo-treated patients (0.47 versus 0.83 mg/h). In addition, 44% (79 of 178 patients) of dexmedetomidine patients received no morphine sulfate for pain versus 19% (33 of 175 patients) in the placebo group.
In the second study, 198 adult patients were randomised to receive placebo and 203 to receive dexmedetomidine by intravenous infusion at a dose of 0.4 microgram/kg/hr (with allowed adjustment between 0.2 and 0.7 microgram/kg/hr) following an initial loading infusion of 1 (one) microgram/kg IV over 10 minutes. The study drug infusion was adjusted to maintain a Ramsay sedation score of ≥ 3. Patients were allowed to receive "rescue" propofol as needed to augment the study drug infusion. In addition, morphine sulfate was administered as needed for pain. The primary outcome measure for this study was the total amount of rescue medication (propofol) needed to maintain sedation as specified while intubated.
Patients randomised to placebo received significantly more propofol than patients randomised to dexmedetomidine (see Table 9).
A significantly greater percentage of patients in the dexmedetomidine group compared to the placebo group maintained a Ramsay sedation score of ≥ 3 without receiving any propofol rescue (see Table 9).

Mortality in ICU patients ≤ 65 years old.

In the SPICE III pragmatic randomised controlled trial of 3904 critically ill adult ICU patients dexmedetomidine was used as primary sedative and compared with usual care. There was no overall difference in 90-day mortality between the dexmedetomidine and usual care group (mortality 29.1% in both groups), but a heterogeneity of effect from age on mortality was observed. Dexmedetomidine was associated with an increased mortality in the age-group ≤ 65 years (odds ratio 1.26; 95% credibility interval 1.02 to 1.56) compared to alternative sedatives. While the mechanism is unclear, this heterogeneity of effect on mortality from age was most prominent in patients admitted for reasons other than post-operative care, and increased with increasing APACHE II scores and with decreasing age. These findings should be weighed against the expected clinical benefit of dexmedetomidine compared to alternative sedatives in younger patients.
In the published study, exposure to dexmedetomidine was greater than 24 hours with a median duration of treatment of 2.56 days (interquartile range, 1.10 to 5.23). The administration of dexmedetomidine was continued as clinically required for up to 28 days after randomization (see Section 4.4 Special Warnings and Precautions for Use).

ICU sedation - elderly.

A total of 729 patients in the clinical studies were 65 years of age and over. A total of 200 patients were 75 years of age and over. In patients greater than 65 years of age, a higher incidence of bradycardia and hypotension was observed following administration of dexmedetomidine (see Section 4.4 Special Warnings and Precautions for Use).
Consideration should be given to lower initial loading and maintenance doses in patients > 65 years and careful monitoring for the development of hypotension when up titrating the maintenance dose (see Section 4.2 Dose and Method of Administration).
Procedural sedation. The safety and efficacy of dexmedetomidine for sedation of non-intubated patients prior to and/or during surgical and other procedures was evaluated in two randomised, double-blind, placebo-controlled multicentre clinical trials. Study 1 evaluated the sedative properties of dexmedetomidine in patients having a variety of elective surgeries/procedures performed under monitored anaesthesia care. Study 2 evaluated dexmedetomidine in patients undergoing awake fibreoptic intubation (AFOI) prior to a surgical or diagnostic procedure.
In Study 1, the sedative properties of dexmedetomidine were evaluated by comparing the percent of patients not requiring rescue midazolam to achieve a specified level of sedation using the standardised observer's assessment of alertness/sedation scale (see Table 10) between dexmedetomidine and placebo.

Patients were randomised to receive a loading infusion of either dexmedetomidine 1 microgram/kg or dexmedetomidine 0.5 microgram/kg, or placebo (normal saline) given over 10 minutes and followed by a maintenance infusion started at 0.6 microgram/kg/hr. The maintenance infusion of study drug could be titrated from 0.2 microgram/kg/hr to 1 microgram/kg/hr to achieve the targeted sedation score (OAA/S ≤ 4). Patients were allowed to receive rescue midazolam as needed to achieve and/or maintain an OAA/S < 4. After achieving the desired level of sedation, a local or regional anaesthetic block was performed. Demographic characteristics were similar between the dexmedetomidine and placebo groups. Efficacy results showed that dexmedetomidine was significantly more effective than placebo when used to sedate non-intubated patients requiring monitored anaesthesia care during surgical and other procedures (see Table 11).
In Study 2, the sedative properties of dexmedetomidine were evaluated by comparing the percent of patients requiring rescue midazolam to achieve or maintain a specified level of sedation using the Ramsay sedation scale [RSS] score > 2 (see Table 7) during AFOI. Patients were randomised to receive a loading infusion of 1 microgram/kg dexmedetomidine or placebo (normal saline) given over 10 minutes followed by a fixed maintenance infusion of 0.7 microgram/kg/hr. After achieving the desired level of sedation, topicalisation of the airway occurred. Patients were allowed to receive rescue midazolam as needed to achieve and/or maintain an RSS score > 2. Demographic characteristics were similar between the dexmedetomidine and placebo groups. See Table 11.

Procedural sedation - elderly.

A total of 131 patients in the clinical studies were 65 years of age and over. A total of 47 patients were 75 years of age and over. Hypotension occurred at a higher incidence in dexmedetomidine-treated patients 65 years or older (71.9%) and 75 years or older (73.5%) as compared to patients < 65 years (46.8%). The loading dose may be omitted or reduced and a reduction in the maintenance infusion should be considered for patients greater than 65 years of age (see Section 4.2 Dose and Method of Administration).
Paediatric studies. A US double-blind and two open-label studies in ICU sedation did not meet their primary efficacy endpoint, and the safety data were insufficient to fully characterise the safety profile of dexmedetomidine.
One open-label ICU sedation study conducted in Japanese patients did meet its primary efficacy endpoint.
The safety profile of dexmedetomidine in these studies was generally similar to that of adults, although increased frequencies of adverse events of bradycardia, hypotension, and respiratory depression were seen in the Japan ICU sedation study.
One open-label study conducted in paediatric patients for procedural sedation also did not meet its efficacy endpoint.

5.2 Pharmacokinetic Properties

Following intravenous administration, dexmedetomidine exhibits the following pharmacokinetic characteristics: rapid distribution phase with a distribution half-life (t_½) of about six minutes; terminal elimination half-life (t_½) approximately two hours; steady-state volume of distribution (V_ss) approximately 118 litres. Clearance (CL) has an estimated value of about 39 L/h. The mean body weight associated with this clearance estimate was 72 kg.
Dexmedetomidine exhibits linear kinetics in the dosage range of 0.2 to 0.7 microgram/kg/hr when administered by IV infusion for up to 24 hours. Table 12 shows the main pharmacokinetic parameters when dexmedetomidine was infused (after appropriate loading doses) at maintenance infusion rates of 0.17 microgram/kg/hr (target concentration of 0.3 nanogram/mL) for 12 and 24 hours, 0.33 microgram/kg/hr (target concentration of 0.6 nanogram/mL) for 24 hours, and 0.70 microgram/kg/hr (target concentration of 1.25 nanogram/mL) for 24 hours.

Distribution.

The steady-state volume of distribution (V_ss) of dexmedetomidine is approximately 118 litres. Dexmedetomidine protein binding was assessed in the plasma of normal healthy male and female volunteers. The average protein binding was 94% and was constant across the different concentrations tested. Protein binding was similar in males and females. The fraction of dexmedetomidine that was bound to plasma proteins was statistically significantly decreased in subjects with hepatic impairment compared to healthy subjects. The potential for protein binding displacement of dexmedetomidine by fentanyl, ketorolac, theophylline, digoxin and lidocaine was explored in vitro, and negligible changes in the plasma protein binding of dexmedetomidine were observed. The potential for protein binding displacement of phenytoin, warfarin, ibuprofen, propranolol, theophylline and digoxin by dexmedetomidine was explored in vitro and none of these compounds appeared to be significantly displaced by dexmedetomidine.

Metabolism.

Dexmedetomidine undergoes almost complete biotransformation with very little unchanged dexmedetomidine excreted in urine and faeces. Biotransformation involves both direct glucuronidation as well as cytochrome P450 mediated metabolism. The major metabolic pathways of dexmedetomidine are: direct N-glucuronidation to inactive metabolites; aliphatic hydroxylation (mediated primarily by CYP2A6) of dexmedetomidine to generate 3-hydroxydexmedetomidine, the glucuronide of 3-hydroxydexmedetomidine, and 3-carboxydexmedetomidine; and N-methylation of dexmedetomidine to generate 3-hydroxy-N-methyldexmedetomidine, 3-carboxy-N-methyldexmedetomidine, and N-methyldexmedetomidine-O-glucuronide.

Excretion.

The terminal elimination half-life (t_½) of dexmedetomidine is approximately 2 hours and clearance is estimated to be approximately 39 L/h. A mass balance study demonstrated that after nine days an average of 95% of the radioactivity, following IV administration of radiolabelled dexmedetomidine, was recovered in the urine and 4% in the faeces. No unchanged dexmedetomidine was detected in the urine. Approximately 85% of the radioactivity recovered in the urine was excreted within 24 hours after the infusion. Fractionation of the radioactivity excreted in urine demonstrated that products of N-glucuronidation accounted for approximately 34% of the cumulative urinary excretion. In addition, aliphatic hydroxylation of parent drug to form 3-hydroxydexmedetomidine, the glucuronide of 3-hydroxydexmedetomidine, and 3-carboxydexmedetomidine together represented approximately 14% of the dose in urine. N-methylation of dexmedetomidine to form 3-hydroxy-N-methyldexmedetomidine, 3-carboxy-N-methyldexmedetomidine, and N-methyldexmedetomidine-O-glucuronide accounted for approximately 18% of the dose in urine. The N-methyl metabolite itself was a minor circulating component and was undetected in urine. Approximately 28% of the urinary metabolites have not been identified.

Specific populations.

Patients with hepatic impairment.

In subjects with varying degrees of hepatic impairment (Child-Pugh Class A, B, or C), clearance values were lower than in healthy subjects. The mean clearance values for subjects with mild, moderate, and severe hepatic impairment were 74%, 64% and 53%, of those observed in the normal healthy subjects, respectively. Mean clearances for free drug were 59%, 51% and 32% of those observed in the normal healthy subjects, respectively.
Although dexmedetomidine hydrochloride is dosed to effect, it may be necessary to consider dose reduction depending on the degree of hepatic impairment (see Section 4.2 Dose and Method of Administration).

Patient with renal impairment.

Dexmedetomidine hydrochloride pharmacokinetics (C_max, T_max, AUC, t_½, CL, and V_ss) were not different in subjects with severe renal impairment (Cr Cl: < 30 mL/min) compared to healthy subjects.
In view of the limited toxicological data and the potential for higher plasma metabolite concentrations in patients with severe renal impairment, caution is advised with prolonged dosing in such patients (see Section 4.2 Dose and Method of Administration).

Male and female patients.

No difference in dexmedetomidine hydrochloride pharmacokinetics due to gender was observed.

Elderly.

The pharmacokinetic profile of dexmedetomidine hydrochloride was not altered by age. However, as with many drugs, the elderly may be more sensitive to the effects of dexmedetomidine. In clinical trials, there was a higher incidence of bradycardia and hypotension in elderly patients.

Children.

The pharmacokinetic profile of dexmedetomidine hydrochloride has not been studied in children.

5.3 Preclinical Safety Data

Genotoxicity.

Dexmedetomidine was not mutagenic in vitro, in either the bacterial reverse mutation assay (E. coli and Salmonella typhimurium) or the mammalian cell forward mutation assay (mouse lymphoma). In a mouse micronucleus study, dexmedetomidine was not cytotoxic to bone marrow and did not increase the numbers of micronucleated PCEs at any dose tested, both in animals maintained at room temperature and in those kept warm. In addition, dexmedetomidine did not induce chromosomal aberrations in cultured human peripheral blood lymphocytes in the absence or presence of an exogenous metabolic activation system comprised of a human S9 homogenate.

Carcinogenicity.

Animal carcinogenicity studies have not been performed with dexmedetomidine.

6 Pharmaceutical Particulars

6.1 List of Excipients

Sodium chloride, water for injections.

6.2 Incompatibilities

Compatibility of dexmedetomidine with co-administration of blood, serum, or plasma has not been established. Dexdor must not be mixed with other medicinal products or diluents except those mentioned in Section 4.2 Dose and Method of Administration, Compatibility.
Dexdor has been shown to be incompatible when administered with the following drugs: amphotericin B, diazepam (see Section 4.4 Special Warnings and Precautions for Use).

Compatibility with natural rubber.

Compatibility studies have demonstrated the potential for absorption of dexmedetomidine to some types of natural rubber (see Section 4.2 Dose and Method of Administration, Compatibility).

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.
Use as soon as practicable after dilution to reduce microbiological hazard. If storage is necessary, hold at 2 - 8°C for not more than 24 hours.

6.4 Special Precautions for Storage

Store below 25°C. Protect from light. Store in the original container.

6.5 Nature and Contents of Container

Dexdor dexmedetomidine (as hydrochloride) 200 micrograms/2 mL concentrated injection is supplied in a 2 mL clear Type 1 glass ampoule. Available in pack sizes of 5 or 25 ampoules.
Dexdor dexmedetomidine (as hydrochloride) 400 micrograms/4 mL concentrated injection is supplied in a 4 mL clear Type 1 glass vial closed with a grey fluoropolymer-coated bromobutyl stopper and flip-off cap. Available in pack sizes of 4 vials.
Dexdor dexmedetomidine (as hydrochloride) 1000 micrograms/10 mL concentrated injection is supplied in a 10 mL clear Type 1 glass vial closed with a grey fluoropolymer-coated bromobutyl stopper and flip-off cap. Available in pack sizes of 4 vials.
Not all pack sizes may be available.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Dexmedetomidine hydrochloride is a white or almost white powder, freely soluble in water and its pKa is 7.1. The partition coefficient in octanol: water at pH 7.4 is 2.89.
Dexdor concentrated injection is preservative-free and contains no additives or chemical stabilisers.

Chemical structure.

Dexmedetomidine hydrochloride is chemically described as (+)-4-(S)-[1-(2, 3-dimethylphenyl)ethyl]-1H-imidazole monohydrochloride and has a molecular weight of 236.7 and the empirical formula is C₁₃H₁₆N₂.HCl. The structural formula is:

CAS number.

145108-58-3.

7 Medicine Schedule (Poisons Standard)

S4 - Prescription Only Medicine.

Service Unavailable

Consumer medicine information

Dexdor

Dexmedetomidine

Keep track of your medicines

BRAND INFORMATION